Allogene Therapeutics (NASDAQ:ALLO – Get Rating)‘s stock had its “outperform” rating restated by research analysts at William Blair in a report released on Wednesday, PriceTargets.com reports. Other equities research analysts have also issued reports about the company. JPMorgan Chase & Co. upgraded Allogene Therapeutics from a “neutral” rating to an “overweight” rating and reduced their […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) – Investment analysts at Zacks Research issued their FY2025 earnings per share (EPS) estimates for Allogene Therapeutics in a report released on Tuesday, March 14th. Zacks Research analyst S. Ganoria anticipates that the company will earn ($2.61) per share for the year. The consensus estimate for Allogene Therapeutics’ […]